Track NTHI and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
NeOnc Technologies Holdings, Inc. Common Stock
23975 Park Sorrento, Calabasas, CA, United States, 91302
IPO
2025
Employees
5
Industry
Biotechnology
Sector
Healthcare
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q2 20260+8
8
Q4 20250+3
3
Q2 20250+9
9
3-quarter cumulative
0 sells20 buys
Analyst Ratings
No coverage data
No analyst ratings data available